- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.12.25 | Samsung Biologics pays GSK $280M to secure first US manufacturing site | ||
| 19.12.25 | 9 pharma giants reach US drug price deals with Trump administration | ||
| 19.12.25 | AstraZeneca to pull bleeding reversal agent Andexxa after FDA flags risk imbalance | ||
| 19.12.25 | FDA outlined concerns with Elevidys manufacturing at Catalent site, Form 483 shows | ||
| 19.12.25 | BioMarin makes largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus | ||
| 19.12.25 | BMS' Cobenfy TV ad is latest target of FDA untitled letter spree | ||
| 19.12.25 | Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement | ||
| 19.12.25 | Cybin alters state to become Helus Pharma for Nasdaq trip | ||
| 19.12.25 | A year in review and what 2026 holds for biopharma and healthcare | ||
| 19.12.25 | 2026 forecast: Pharma clicks with patients as direct sales model shifts marketing strategies | ||
| 18.12.25 | Medtronic encourages people with Type 1 diabetes to 'Own It' in new MiniMed campaign | ||
| 18.12.25 | High-flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri | ||
| 18.12.25 | J&J scores FDA nod for subcutaneous lung cancer shot, sharpening its challenge to Tagrisso | ||
| 18.12.25 | Bicycle gets radiopharmaceutical push from UK pact for reprocessed uranium | ||
| 17.12.25 | Biosecure Act heads to Trump's desk with defense spending bill after Senate vote | ||
| 17.12.25 | 'Our work is never over': How Lilly's 2026 Olympics team-ups align with its own mission | ||
| 17.12.25 | Intercept, on heels of Ocaliva withdrawal, restructures with 146 layoffs | ||
| 17.12.25 | With pivotal trial underway, Ionis ramps up Angelman syndrome awareness with Lifetime TV segment | ||
| 17.12.25 | Alnylam lays out $250M to equip flagship facility with cutting-edge siRNA production tech | ||
| 17.12.25 | Hansa falls short in bid to push EU-approved kidney transplant drug into new autoimmune indication | ||
| 17.12.25 | Keytruda, Padcev keep winning streak with another patient survival benefit in bladder cancer | ||
| 16.12.25 | Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drug | ||
| 16.12.25 | Fosun Pharma signs up to take on China's Green Valley, revive controversial Alzheimer's med | ||
| 16.12.25 | Avalere taps longtime Senate staffer to head up healthcare policy team amid regulatory turbulence | ||
| 16.12.25 | Pfizer shares drop 5% with 2026 revenue projection and long-range outlook |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .